Lineage Cell Therapeutics, Inc. · AMEX:LCTX
Lineage Cell Therapeutics — Biotime — ASNTR 26th Annual Conference 2019
25 slides from Lineage Cell Therapeutics's conference presentation, Apr 29, 2019
Slide 1: Top-line 12-month Results from the SCiStar Study
Exhibit 99.2 = BIOTIME NYSE American: BTX Top-line 12-month Results fro e SCiStar Study - A Phase 1/2a Trial of Human Embryonic Stem Cell-Derived Oligodendrocyte Progenitor Cells (OPC1) in Patients with Subacute Cervical Spinal Cord Injury Edward D. Wirth, Ill, MD, PhD ASNTR 26* Annual Conference Ap
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation is for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any securities of BioTime, Inc. (“BioTime” or the “Company”). This presentation includes certain information obtained from trade and statistical services,
Slide 3: OPC1: hESC-Derived Oligodendrocyte Progenitor Cells
OPC1: hESC-Derived Oligodendrocyte Progenitor Cells (QP BIOTIME OPC1 » Cryopreserved Allogeneic Cell Population » Derived from an NIH-Registered Human Embryonic Stem Cell line (hESC) » Characterized Composition of Cells: + Oligodendrocyte progenitors » Neural progenitors » Infrequent mature neural c
Slide 4: OPC1 functions: myelination, neurotrophic factors, neovascularization
1. Wraps hostneurons 2. Produces neurotrophic factors and stimulates neurite and forms compact myelin sheaths* outgrowth** shiverer mouse —— Eis ; 2 » shi mouse + OPC1 Control Media OPC1CM 3. Stimulates neovascularization* Host Endothelial Cells » . Soh Rag2/-yc/-/shi mouse + OPC1 5 Rat spinal cord
Slide 5: SCiStar Study Schema
SCiStar Study Schema * Open Label Trial Primary Assessment: Safety * 21-42 days post SCI Secondary Assessment: Neurological * Traumatic cervical SCI (C4-C7) Function (ISNCSCI exams) * Ages 18-69 Exploratory Assessments: SCIM, GRASSP ° AISAorB [a Protocol OPC1-01 | Protocol OPC1-02 | MRI MRI MR MRI M
Slide 6: SCiStar dose escalation cohorts
AIS-A AIS-B BIOTIME Cohort 1 3 subjects with AIS- ACS5-C7 cervical SCI Dose 2x10° cells Escalation Cohort 2 Cohort 3 6 subjects AIS-A 6 subjects with AIS-A C4-C7 cervical SC! ———>| C4-C7 cervical SCI Dose Escalation Dose 1x10’ cells Dose 2x10’ cells ¥ Cohort 4 Cohort 5 6 subjects wit 4 subjects with
Slide 7: Follow-Up Status for SCiStar Study
Follow-Up Status for SCiStar Study | #Subjects | #Subjectswith | ysubjects with # Subjects with Administered | 12 Months opc1 followsp 2 Years LTFU 3 Years LTFU Safety Cohort 1 AIS-A a 2 3 3 2x10® Dose Safety and Efficacy Cohort 2 AIS-A 6 6 6 2 1x10 Dose Safety and Efficacy Cohort 3 AIS-A e 6 2 = 2x
Slide 8: OPC1 Injection Procedure
OPC1 Injection Procedure Shepherd Center > Rush University Injections performed using a table-mounted syringe positioning device (SPD) Direct intra- parenchymal injection into the spinal cord lesion Single 50yuL injection for both the 2M & 10M doses; Two injections for the 20M dose No intraoperative
Slide 9: 12-Month MRI Results Support Durable Engraftment of OPC1
12 Month MRI Results Support Durable Engraftment of OP Cohort 2 subject > Cavitation is estimated to occur in~80% of _2°2Dav 12 weighted sagittal MRI spinal cord injury patients meeting SCiStar Study inclusion criteria Vv 96% (24/25) of subjects had serial MRI scans at 12 months that indicated no si
Slide 10: Some Lesions May Be Too Severe for OPC1 Cell Survival
Some Lesions May Be Too Severe for OPC1 Cell Sur Pre-Injection Baseline Day 365 Post-Injection =A ‘ Uy Failed graft with lesion cavity formation > Large hematomain spinal cord > Most severe lesion at baseline > Least favorable environment for survival of OPC1 cells = BIOTIME 10
Slide 11: SCiStar Study Primary Endpoint: Safety
SCiStar Study Primary Endpoint: Safety Tolerability Also Assessed > SCiStar Study primary endpoint was met: * Safety assessed by the frequency and severity of adverse events (AE) related to OPC1, the injection procedure, and immunosuppression with short-term, low-dose tacrolimus > No concerning safe
Slide 12: SCiStar Study Summary of Adverse Events
SCiStar Study Summary of Adverse Events= > Majority of SCiStar Study adverse events were mild to moderate in severity All Treated Subjects (n=25) AEs SAEs Total 534 29 Mild (Grade 1) 343 0 Moderate (Grade 2) 161 15 Severe (Grade 3) 30 14 Life threatening (Grade 4) (0) 0 Death (Grade 5) (1) (0) Relat
Slide 13: SCiStar Study Most Common SAEs
SCiStar Study Most Common SAEs All Treated Subjects SAE # Causality (N=25) Total 29 27 not related UTI 7 Not related Urinary Sepsis 2 Not related Pulmonary Embolus 2 Not related Mental Status Changes 2 Not related CSF Fluid Leak 1 Related to Injection Procedure Infected Epidural Fluid 1 Related to T
Slide 14: SCiStar Study Most Common AEs
SCiStar Study Top 5 Most Common AEs All Treated AE # Causality* Subjects (N=25) Total 534 402 not related AEs UTI 60 60 not related Decubitus Ulcer 37 37 not related Hypokalemia 24 24 not related Hypomagnesemia 16 8 related to tacrolimus Headache 15 2 related to injection procedure >» *Related to ei
Slide 15: Neurological Function Assessment: ISNCSCI
Neurological Function Assessment: International Standards for Neurolégiegt Classification of Spinal Cord Injury (ISNCSCI) pers 2 ize rowenta (ren eld) eerste Lk opie ona LS ‘en parts St 2 3 (ot a ant fee] 8 ae a [wesc sensory susscones vuee[_]+e[_]e uens rom (—} jfr{—]otee{—Jocews rom (—] er] urL_]s
Slide 16: Upper Extremity Motor Score Recovery in Cohorts
Upper Extremity Motor Score (UEMS) Recovery in Cohorts 2 Fs +2 Motor Levels UEMS Improvement 6 Months 12 Months 6 Months 12 Months Cohort 2 2/6 4/6 ey) 12.3 Cohort 3 1/6 1/6 6.0 92) Cohort 4 1/6 1/6 5) 6.7 Cohort 5 0/4 1/4 5.8 6.8 Cohorts 2-5 4/22 7/22 6.8 8.9 +/- 4.2 > Next step was to look all 22
Slide 17: Subjects with the Least Motor Recovery (Cohorts 2-5)
Subjects with the Least Motor Recovery (Cohorts 2-5 UEMS Change 2 Motor Injection from level Date Days Baseline Gain from Baseline LI ject to12mo Y/N Cohort Dose Lot Age Injury —AIS__ Baseline ES N 5 20 million M22 62 37 B [= | 2203 6 N 3 20 million M25 45 31 A cé 6 N a" 10 million M25 19 20 A foe |
Slide 18: SCiStar Study Preliminary Subset Analysis
SCiStar Study Preliminary Subset Analysis Cohort Comments Cohort 2 6 4 12.3 2S A A etms 5 1 8.8 2105 had C4 NLI*, severe lesion and failed graft 2303 had cord compression at Day 30 Cohort 4 4 1 8.0 2007 had C4 NLI 2307 had cord compression at Day 7 Gime | 2 1 85 2207 had C4 NLI Total 7 7 10.2 4/- 3.
Slide 19: Evaluation of Change in UEMS Versus Key Variables
SCiStar Study Evaluation of Change in UEMS (12 Months Post-Injection Versus Key Variables) * Analysis performed for all 22 subjects in Cohorts 2-5 (except for Baseline NLI, which was only analyzed for subjects with a baseline NLI of C5, C6 or C7) iable Gender Baseline AIS Grade Baseline NLI (C5-C7)
Slide 20: Exploratory Assessment: Spinal Cord Independence Measure
Exploratory Assessment: Spinal Cord Independence Measure (scinaty > SCIMisa “global” functional activities exam within the activity/function domain (does not cover pain, spasticity, or autonomic functions) > Maximum score of 100 comes from 3 sub-scales within SCIM (self-care = 20 points, respiration
Slide 21: Change in SCIM Total Score did not correlate with UEMS
Change in SCIM Total Score did not correlate with Gems Change from baseline: UEMS vs SCIM Total Correlation R = 0.01 wo a. 3 Cohort & 2 3 a3 § 4 $ ——— a g ~ 8 r ts =| 5 re) 8 é $ 10 15 2 a UEMS Change from Baseline to 12 months = BIOTIME a
Slide 22: SCIM Self-Care Subscore Poorly Correlated with UEMS
Change in SCIM Self-Care Subscore is Poorly Correlated withSems Change from baseline: UEMS vs SCIM Self Care Correlation R = 0.08 . * Will review with reordered SCIM data per the Rasch analysis used to develop the Spinal Cord Ability 2°] : s Ruler (SCAR)* outcome 5 eS cohort ©="easure to assess util
Slide 23: Summary
Summary v The overall safety profile of OPC1 to date is excellent, and immunosuppression with tacrolimus was well-tolerated > MRI scans are consistent with a very high rate (96%) of durable engraftment through 1 year post-injection » Majority of subjects who received 10M or 20M OPC1 cells exhibited
Slide 24: Acknowledgments
Acknowledgments Asterias* Jane Lebkowski Katy Spink Susy Chen Maria Schaefer Sherin Halfon Oliver Tilk Rekha Nair Maggie Morysewicz Kevin Nishimoto Naomi Kautz OPC1 Team BIOTIME Clinical Investigators The Trial Participants Don Leslie Kevah Khajavi Richard Fessler Committees & James Young Consultant
Slide 25: NYSE American: BTX
NYSE American: BTX